Document is current

Article History

Accepted: 4 November 2024

First Online: 30 November 2024

Declarations

:

: Open Access funding enabled and organized by Projekt DEAL. This study received funding from Chiesi GmbH, Germany (investigator initiated non-interventional studies: DJUS21002971, DJUS13008931, DJUS13011311). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of the article, or the decision to submit it for publication.

: ML received research/travel grants and/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Sumitomo Pharma, and Takeda. EB received research grants and/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Takeda, and Eleva. MR received speaker honoraria, congress support, and research grants from Sanofi, Chiesi, and Amicus Therapeutics. MC received speaker honoraria/travel grants from Takeda, Amicus Therapeutics, Idorsia, and Alexion. ERM has nothing to declare.

: The original contributions presented in the study are included in the article and Online Resources; further inquiries can be directed to the corresponding author.

: All investigations were performed after approval by the Medical Association of Westphalian-Lippe and the Ethics Committee of the Medical Faculty of the University of Muenster (project no. 2011-347-f, date of report: 7 July 2011) and in accordance with the Declaration of Helsinki.

: Written informed consent was obtained from all included patients for analysis and publication.

: Not applicable

: All authors have contributed to the article by participating in the conception and design (ML), acquisition of data (ML, ERM, MR, MC, EB) or formal analysis (ML, ERM) and interpretation of data (ML, EB), drafting the article (ML, EB) or revising it critically for important intellectual content (ERM, MR, MC). All authors read and approved the final version of the manuscript.